Eyerising International
Eyerising International is an Australian medical technology company developing treatments to slow the progression of myopia. The Eyerising Myopia Management Device uses repeated low-level red-light therapy to the back of the eye. This stimulates blood flow and thickens the choroid, the layer at the back of the eye, which helps reduce eye elongation and slow myopia progression.
Eyerising International myopia management products
Myopia management products listed by Myopia Profile have been specifically designed for myopia control or myopia management in children, and have some form of regulatory approval or marking for this form of use. They also have randomized controlled trial research data supporting their efficacy, unless otherwise noted. It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.
Eyerising Myopia Management Device
The Eyerising Myopia Management Device uses Repeated Low-Level Red-Light (RLRL) therapy, delivering 650nm visible red light to the back of the eye. This treatment has been shown to improve blood flow and thicken the choroid, which may help address scleral hypoxia linked to myopia progression. The device is supported by more than 40 clinical studies, including two-year trial results showing it can slow myopia progression.